Medicamen Biotech has proposed a 10% final dividend and reported strong Q1 profit growth. The company also disclosed a Rs 1.10 lakh compliance fine paid to exchanges.
Medicamen Biotech Proposes 10% Dividend, Q1 Profit Surges 54%
Medicamen Biotech Ltd announced a proposed final dividend of 10% (Re. 1 per share) for the financial year, subject to shareholder approval at the 33rd Annual General Meeting (AGM) on September 26, 2026. The record date for dividend eligibility is September 19, 2026. Reader Takeaway: Strong profit growth offers returns, but a regulatory fine flags governance. ## What just happened The company reported a 54.3% increase in standalone net profit to Rs 2.53 crore for the quarter ended June 30, 2026, compared to Rs 1.64 crore in the same quarter last year. Standalone revenue grew by 14.9% to Rs 44.71 crore. On a consolidated basis, net profit rose 15.6% to Rs 1.85 crore, with revenue up 12.0% to Rs 48.76 crore. The company also disclosed a compliance fine of Rs 1,10,920, paid to BSE and NSE for non-compliance with SEBI (LODR) Regulations, 2015, concerning the Nomination and Remuneration Committee. ## Why this matters The significant profit growth indicates improved operational performance and profitability for Medicamen Biotech. The proposed dividend offers a direct return to shareholders. However, the regulatory fine, while paid, points to a past governance lapse that investors should monitor for future adherence. ## The backstory Medicamen Biotech is a pharmaceutical company engaged in the manufacturing and export of various pharmaceutical formulations. The company has a history of dividend payouts, and its Q1 results follow a period of operational focus. ## What changes now Shareholders will await the AGM outcome for final dividend approval. The management is expected to implement corrective measures to prevent future regulatory non-compliance. The financial results suggest a positive trajectory for the current fiscal year. ## Risks to watch While the fine has been paid, continued adherence to SEBI regulations, particularly concerning board committees, is crucial to avoid future penalties or scrutiny. ## Peer comparison Medicamen Biotech operates in the competitive pharmaceutical sector, where revenue and profit growth are closely watched. Its peers often show similar revenue growth trends, but profit margins can vary significantly based on product mix and market reach. ## Context metrics (time-bound) * Standalone Revenue (Q1 FY27): Rs 44.71 crore (up 14.9% YoY) * Standalone Net Profit (Q1 FY27): Rs 2.53 crore (up 54.3% YoY) * Consolidated Revenue (Q1 FY27): Rs 48.76 crore (up 12.0% YoY) * Consolidated Net Profit (Q1 FY27): Rs 1.85 crore (up 15.6% YoY) ## What to track next Investors should track the company's compliance status, future dividend announcements, and its performance in subsequent quarters against its growth targets.
